Dr Oliver Davidson is Consultant Clinical Psychologist and Head of HIV and Sexual Health Psychology Services at Camden NHS Primary Care Trust. He is Chair of the British Psychological Society DCP HIV and Sexual Health Faculty. He has no conflicts of interest to disclose.

Dr James Deutsch was Chief Executive at Crusaid during the preparation of this document. Crusaid is funded primarily by voluntary donations from individuals but also receives a small amount of funding from most of the major pharmaceutical companies in the HIV/AIDS field including GlaxoSmithKline, Bristol-Myers Squibb and Boehringer Ingelheim.

Dr Martin Fisher is Consultant Physician HIV/GUM at Brighton and Sussex University Hospitals NHS Trust. He is an Executive Committee Member of BHIVA, and Chair of the HIV Special Interest Group of BASHH. He sits on advisory boards for Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, and Roche, and has received unrestricted educational grants for research from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead and GlaxoSmithKline.

Dan Godfrey is Principal HIV Pharmacist at the Department of Pharmacy and Department of Genitourinary Medicine, Mayday Hospital, and an executive committee member of the HIV Pharmacy Association. He is a member of the UK Pharmacy Advisory Board of Bristol-Myers Squib. He has also received unrestricted education and travel grants to attend conferences from GlaxoSmithKline, Bristol-Myers Squib, Boehringer Ingelheim, Roche, Abbott and Gilead. He has undertaken consultancy work for GlaxoSmithKline.

Stephen Head was Clinical Nurse Specialist at the Family HIV Clinic, St Mary’s Hospital during the preparation of this document. He has received unrestricted educational grants from GlaxoSmithKline, Abbott, Roche, Bristol-Myers Squibb, Gilead and Boehringer Ingelheim.

Professor Rob Horne is Professor of Psychology in Health Care and Director of the Centre for Health Care Research at the University of Brighton. He is a consultant to GlaxoSmithKline, Schering Plough and Merck Sharp and Dohme, and has received unrestricted educational grants for research from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pharmacia, and Astra Zeneca.

Anna Poppa is a freelance Medical Writer. She has worked as a consultant to GlaxoSmithKline and Boehringer Ingelheim.

Professor Lorraine Sherr is Professor of Clinical and Health Psychology at the Royal Free University College Medical School. HEFCE funded. Lorraine is currently a member of GlaxoSmithKline’s Adherence Strategy Group. She has undertaken national and international research funded by the Medical Research Council, Europe, Camden and Islington Health Trust.

Thanks to Thomas Paterson for proof-reading the final draft.